KR102307387B1 - 표적화된 화학요법에 사용하기 위한 비­백금­기반 항암 화합물 - Google Patents

표적화된 화학요법에 사용하기 위한 비­백금­기반 항암 화합물 Download PDF

Info

Publication number
KR102307387B1
KR102307387B1 KR1020167012036A KR20167012036A KR102307387B1 KR 102307387 B1 KR102307387 B1 KR 102307387B1 KR 1020167012036 A KR1020167012036 A KR 1020167012036A KR 20167012036 A KR20167012036 A KR 20167012036A KR 102307387 B1 KR102307387 B1 KR 102307387B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
compound
cells
npb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167012036A
Other languages
English (en)
Korean (ko)
Other versions
KR20160070784A (ko
Inventor
큉-빈 루
Original Assignee
큉-빈 루
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큉-빈 루 filed Critical 큉-빈 루
Publication of KR20160070784A publication Critical patent/KR20160070784A/ko
Application granted granted Critical
Publication of KR102307387B1 publication Critical patent/KR102307387B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167012036A 2013-10-08 2014-10-08 표적화된 화학요법에 사용하기 위한 비­백금­기반 항암 화합물 Expired - Fee Related KR102307387B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887988P 2013-10-08 2013-10-08
US61/887,988 2013-10-08
PCT/CA2014/050974 WO2015051458A1 (en) 2013-10-08 2014-10-08 Non-platimun-based anti-cancer compounds for use in targeted chemotherapy

Publications (2)

Publication Number Publication Date
KR20160070784A KR20160070784A (ko) 2016-06-20
KR102307387B1 true KR102307387B1 (ko) 2021-09-30

Family

ID=52812401

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167012036A Expired - Fee Related KR102307387B1 (ko) 2013-10-08 2014-10-08 표적화된 화학요법에 사용하기 위한 비­백금­기반 항암 화합물

Country Status (8)

Country Link
US (2) US10463662B2 (enExample)
EP (2) EP3578176A1 (enExample)
JP (1) JP6765302B2 (enExample)
KR (1) KR102307387B1 (enExample)
CN (2) CN106232581A (enExample)
AU (1) AU2014334461B2 (enExample)
CA (1) CA2926571C (enExample)
WO (1) WO2015051458A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219440A1 (en) 2002-04-17 2003-11-27 Annette Tobia 3-deoxyglucosone and skin
WO2006067466A2 (en) 2004-12-22 2006-06-29 The Wellcome Trust Limited Pyrazines and pyridines and derivatives thereof as therapeutic compounds
WO2008082487A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
IL112235A (en) * 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
DE102004054545A1 (de) * 2004-09-16 2006-04-06 Max-Delbrück-Centrum für Molekulare Medizin Änderung des Beladungszustandes von MHC-Molekülen
US20060089316A1 (en) * 2004-10-25 2006-04-27 Brown Truman R Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
US7566718B2 (en) * 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
ES2569660T3 (es) * 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
EP2188276B1 (en) * 2007-08-16 2012-03-28 F. Hoffmann-La Roche AG Substituted hydantoins
DK200801600A (en) * 2008-11-17 2010-05-18 Engkilde Kaare Method for treatment of inflammatory diseases
EP2493862B1 (en) * 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
WO2012096813A1 (en) * 2011-01-11 2012-07-19 Merck Sharp & Dohme Corp. Imidazole derivatives
MX2015008010A (es) 2012-12-20 2016-04-26 qing-bin Lu Compuestos radiosensabilizadores para usarse en combinacion con radiacion.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219440A1 (en) 2002-04-17 2003-11-27 Annette Tobia 3-deoxyglucosone and skin
WO2006067466A2 (en) 2004-12-22 2006-06-29 The Wellcome Trust Limited Pyrazines and pyridines and derivatives thereof as therapeutic compounds
WO2008082487A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. Godemann et al.，Fragment-Based Discovery of BACE1 Inhibitors Using Functional Assays, Biochemistry, 2009, 48, pp.10743-10751

Also Published As

Publication number Publication date
CN106232581A (zh) 2016-12-14
CA2926571A1 (en) 2015-04-16
AU2014334461A1 (en) 2016-04-28
JP6765302B2 (ja) 2020-10-07
KR20160070784A (ko) 2016-06-20
US10463662B2 (en) 2019-11-05
US20160235743A1 (en) 2016-08-18
AU2014334461B2 (en) 2019-06-13
JP2016534048A (ja) 2016-11-04
EP3055287A1 (en) 2016-08-17
US11446294B2 (en) 2022-09-20
EP3578176A1 (en) 2019-12-11
CN114380700A (zh) 2022-04-22
CA2926571C (en) 2022-05-17
WO2015051458A1 (en) 2015-04-16
EP3055287A4 (en) 2017-04-12
US20200009133A1 (en) 2020-01-09
EP3055287B1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
US11446294B2 (en) Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
Leonidova et al. Photo-induced uncaging of a specific Re (I) organometallic complex in living cells
JP6321673B2 (ja) 放射線と組み合わせて使用するための放射線増感剤化合物
Rath et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer
US9238654B2 (en) Singleton inhibitors of sumoylation enzymes and methods for their use
KR20220008869A (ko) 항암 핵 호르몬 수용체-표적화 화합물
ES2898704T3 (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer
Shao et al. Biotinylated curcumin as a novel chemosensitizer enhances naphthalimide-induced autophagic cell death in breast cancer cells
US9867807B2 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
WO2023217093A1 (en) Prodrug activation of n-oxides by radiotherapy
Liu et al. DNA damage-driven cGAS-STING activation via a nuclear-targeted probe enables potent near-infrared theranostics in breast cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240925

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20240925

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240925